Advanced Search

Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection

Contents:

Author Info

  • Eva Susanne Dietrich

    (Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany)

  • Bjorn Schubert

    (Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany)

  • Winfried Ebner

    (Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany)

  • Franz Daschner

    (Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany)

Registered author(s):

    Abstract

    Objective: To compare the cost, efficacy and cost efficacy of tazobactam/ piperacillin and imipenem/cilastatin in the treatment of intra-abdominal infection. Design: The analysis was retrospective and based on a decision tree. Effectiveness data were obtained from 19 published clinical trials. Direct costs were quantified per patient from the time the decision was made to administer the antibacterial to the end of the first course of treatment or the end of a subsequent course of treatment, if required. The primary end-point was the cost per successfully treated patient. The cost per life saved was also analysed. Various follow-up times were taken into account. Perspective: German National Health Insurance funds. Study population: 1744 patients with intra-abdominal infection. Interventions: Tazobactam/piperacillin (total daily dosage of 13.5 g/day) and imipenem/cilastatin (total daily dosage of 1.5 to 4 g/day). The mean duration of treatment varied from 5.5 to 8.2 days for tazobactam/piperacillin and 5 to 9.4 days for imipenem/cilastatin. Main outcome measure and results: Compared with imipenem/cilastatin, treatment with tazobactam/piperacillin was more effective and the overall treatment costs were lower. In the base-case analysis, the cost-efficacy ratio (cost per successfully treated patient) was 7881 German deutschmarks (DM) for tazobactam/ piperacillin and DM11 390 for imipenem/cilastatin. The incremental cost-efficacy ratio (per life saved) varied between -DM72 567 and -DM350 738 for tazobactam/ piperacillin. Sensitivity analyses revealed that the results were robust against various assumptions on cost parameters, clinical outcomes and length of treatment. All costs reflect 1998 values; $US1 = DM1.85. Conclusions: This study suggests that compared with imipenem/cilastatin, tazobactam/piperacillin is more cost efficacious in the treatment of intra-abdominal infections and that it offers a cost advantage through fewer relapses and lower daily therapeutic costs.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-200119010-00006.pdf
    Download Restriction: Pay per view
    File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/fulltext.00019053-200119010-00006.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 19 (2001)
    Issue (Month): 1 ()
    Pages: 79-94
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:phecon:v:19:y:2001:i:1:p:79-94

    Contact details of provider:
    Web page: http://pharmacoeconomics.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords: Antibacterials; Cost analysis; Imipenem/cilastatin; Intra abdominal infections; Pharmacoeconomics; Tazobactam/piperacillin;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:19:y:2001:i:1:p:79-94

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.